drugset / Trial / NCT02072720
Angiogenic Factor Expression During Fractionated Irradiation
Phase 0
Unknown
40 enrolled
Amsterdam UMC, location VUmc
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · collabNoordwest Ziekenhuisgroep · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main question of this study is if and when VEGF (vascular endothelial growth factor) expression in the tumor is upregulated during chemoradiation and if bevacizumab inhibits subsequent vessel growth in the tumor. * Therefore the first aim of this study is to identify the time point of induction of VEGF in the tumor tissue of esophagus carcinoma during chemoradiation (after 1,2,3 or 4 weeks of chemoradiation). * If we identify increased expression of VEGF at a certain time point, our second aim is to determine if we can inhibit the subsequent tumor vessel growth by administration of bevacizumab.
Timeline
- Start
- 2014-02
- Primary completion
- 2021-03
- Completion
- 2021-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 3 mg/kg | — |